Pharmaresearch FY 2025 Annual ReportBeta
Pharmaresearch annual report for FY 2025, filed with DART (Korea Financial Supervisory Service) on March 19, 2026. This page provides AI-powered English analysis including business overview, management discussion & analysis (MD&A), risk factors, and KIFRS consolidated financial data such as revenue, net income, gross margin, operating margin, and return on equity (ROE).
Pharmaresearch FY 2025 Annual Report Analysis
Business Overview
- • Revenue mix FY2025: medical devices 58.6%, cosmetics 24.6%, pharmaceutical products 15.4%, others 1.4%
- • Domestic launch of botulinum toxin product "Rientox 100 units" in April 2025 after Feb 1, 2024 approval
Management Discussion & Analysis
- • Revenue KRW 536.3B (+53% YoY), Operating Profit KRW 214.4B (+70%), Net Income KRW 168.3B (+89%) in FY2025
- • Export segment growth driven by expanded distribution and brand recognition in China, Japan, Southeast Asia, and North America
Risk Factors
- • KRW 9.72B pre-tax profit sensitivity to 10% won appreciation/depreciation against foreign currencies at fiscal year-end 2025
- • KRW 722.5B equity and net cash position with KRW 290.1B negative net borrowings at FY2025-end
Pharmaresearch FY 2025 Key Financial MetricsDART
Total Assets
KRW 1.04T
▲ +22.0% YoY
Operating Cash Flow
KRW 183.2B
▲ +32.6% YoY
CapEx
KRW 29.7B
▼ -18.4% YoY
Source: KIFRS consolidated financial data from Pharmaresearch annual report on DART. All figures in KRW.
Source: DART (Korea Financial Supervisory Service) · AI summaries generated from the original Korean filing (English output) · Beta: coverage is expanding